The Scottish Medicines Consortium has approved Combodart (dutasteride 0.5mg/tamsulosin hydrochloride 0.4mg) for the treatment of benign prostatic hyperplasia (BPH) within NHS Scotland.
The drug is indicated for the treatment of moderate-to-severe BPH and reduction in the risk of acute urinary retention and BPH-related surgery.
Introducing Nursing Times Learning
Subscribers get five FREE learning units and non-subscribers can access each learning unit for £10 + VAT.
Click on the topics below to get started: